



California State Board of Pharmacy
1625 N. Market Blvd, N219, Sacramento, CA 95834
Phone: (916) 574-7900
Fax: (916) 574-8618
www.pharmacy.ca.gov

BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY
DEPARTMENT OF CONSUMER AFFAIRS
GOVERNOR EDMUND G. BROWN JR.

ORDER TO CEASE AND DESIST

Date: September 21 2015

Permit No.: LSC 100404

Name as shown on permit: OROVILLE HOSPITAL - MAIN PHARMACY

Address: 2767 OLIVE HIGHWAY OROVILLE CA 95966

California Business and Professions Code Section 4127.3 provides whenever the Board has a reasonable belief, based on information obtained during an inspection or investigation, a pharmacy compounding injectable sterile drug products poses an immediate threat to the public health or safety, the Board may issue an order to the pharmacy to immediately cease and desist from compounding injectable sterile drug products, which order shall remain in effect for no more than 30 days or the date of a hearing seeking an interim suspension order, whichever is earlier.

Specifically, inspections conducted by the California State Board of Pharmacy (Board) revealed Oroville Hospital Pharmacy (LSC 100404) repeatedly failed to compound sterile injectable drug products pursuant to the regulations, putting the public at risk. On July 6, 2015 and July 30, 2015 the Board provided extensive guidance on compounding to Oroville Hospital's pharmacy and administrative staff. However, Oroville Hospital Pharmacy ignored that guidance and has continued to compound sterile injectable drug products not in compliance with the governing regulations, thereby continually putting the public's health and safety at risk.

The foregoing does or may constitute a violation or violations of California and/or Federal law including but not limited to:

- Health and Safety Code sections 111260, 111285, 111305, 111330, 111440
- Business and Professions Code section 4169(2), 4169(3), 4301(c), 4301(f), 4301(g), 4301(o), 4301(q), 4306.5(a), 4306.5(b), 4306.5(c)
- Title 16 California Code of Regulations sections 1709.1(a), 1714(c), 1735.2(d), 1735.2(f), 1735.2(h), 1735.2(i), 1735.3(a), 1735.7(b), 1735.7(c), 1751.1(a), 1751.3(a), 1751.3(b), 1751.4(a), 1751.4(e), 1751.6(b), and 1751.6(d)
- Title 24 California Code of Regulations sections 1250.4(2)

On the basis of the foregoing, the Board has a reasonable belief that Oroville Hospital sterile injectable compounding practices pose an immediate threat to the public health or safety in California, and therefore **ORDERS:**

Oroville Hospital shall immediately **CEASE AND DESIST** from compounding sterile injectable products. This cease and desist order shall remain in effect for 30 days or until the date of a hearing seeking an interim suspension order, whichever is earlier.

Sep 21 15 12:26p

Inspector CAcosta-BOP

8587151689

p.2

Pursuant to Business and Professions Code section 4127.3, subdivision (c), within 15 days of the receipt of this notice you may request a hearing before the president of the board to contest the cease and desist order.


Additionally, Oroville Hospital shall contact **EACH PRESCRIBER, ENTITY, AND PATIENT** in California for whom Oroville Hospital has prepared sterile injectable medications to determine if the prescriber, entity, or patient has any such preparation in his/her possession. Any such preparation in the possession of prescribers/entities/patients shall be recalled (if not already done). The product is to be returned to Oroville Hospital.

The above-listed materials shall be provided by November 5, 2015 to the California State Board of Pharmacy, Attn: Supervising Inspector Christine Acosta, 1625 North Market Blvd., Suite N-219, Sacramento, CA 95834. You may reach Supervising Inspector Acosta at 619-818-7255.

California State Board of Pharmacy

By: Virginia Herold

Signed:



Date: September 21, 2015

Title: Executive Officer

I hereby acknowledge receipt of the above cease and desist order and notice.

By: Robert J. Wentz

Signed: 

Date: September 21, 2015

Title: President / CEO